The biotech sector's heady end-of-year continued Wednesday, with shares of Cytokinetics surging after the company said its experimental heart drug worked safely in a study. Analysts and investors anticipated the results of aficamten because of the pill’s potential to compete for prescriptions with
Jared S. Hopkins is a journalist who writes for The Wall Street Journal, LiveMint, and Yahoo Finance. He specializes in covering the pharmaceutical industry, including topics such as drug development, pricing, and market trends. With a focus on providing insightful and timely reporting, Jared's articles offer valuable analysis for readers interested in the business and science behind the pharmaceutical world.